FDA Says On Aug 5, Baxter Issues Voluntary Nationwide Recall Of One Lot Of Heparin Sodium 0.9% Sodium Chloride Injection; Baxter Issues Recall Of One Lot Of Heparin Sodium 0.9% Sodium Chloride Injection Due To Potential For Elevated Endotoxin Levels
Portfolio Pulse from Benzinga Newsdesk
Baxter has issued a voluntary nationwide recall of one lot of Heparin Sodium 0.9% Sodium Chloride Injection due to potential elevated endotoxin levels, as reported by the FDA.

August 06, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baxter has issued a voluntary recall of one lot of Heparin Sodium 0.9% Sodium Chloride Injection due to potential elevated endotoxin levels. This recall could impact Baxter's stock in the short term due to potential regulatory scrutiny and customer concerns.
The recall of a medical product due to potential elevated endotoxin levels can lead to regulatory scrutiny and customer concerns, which may negatively impact Baxter's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100